Bosentan Tablet, Film Coated
Product Images NDC 0591-2511

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bosentan (NDC 0591-2511). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

FDA Label Image

1 (Image 10)

This text seems to describe the dosage and accompanying instructions for Bosentan, a medication contained in tablets. The tablets should be stored in a tightly sealed container, at room temperature, and dispensed with an accompanying Medication Guide. The manufacturer is Actavis and the tablet qualifies for the United States Pharmacopeia (USP).*

FDA Label Image

2 (Image 2)

This text seems to be describing a list of drugs and their interactions with each other. It mentions drugs like Cyclosporin A, Lopinaviritonavic, and Riampin, as well as enzymes like OATP and VP34. It also mentions terms like "AT inhiiton", "inducton", "Cmax", "auc", "Fold-change of bosentan", and "ASTIALT weekly". However, the text is not clear and contains typos, making it difficult to interpret.*

FDA Label Image

1 (Image 3)

FDA Label Image

1 (Image 4)

This appears to be a list of drugs and their interactions with other drugs. The list includes information on drug induction and its effects on other drugs. It also provides recommendations on the use of the interacting drug, including contraindications, monitoring cholesterol levels, and the need for additional contraception. Additionally, some drugs may require adjustments to the dosage based on the presence of the interacting drug. There is also information on AUC and Cmax levels in plasma concentrations.*

FDA Label Image

1 (Image 5)

This is a drug interaction recommendation table that suggests adjustments of doses of certain drugs due to the presence of inhibitors and substrates of CYP3A4, CYP2CH, OATP, and ASTIALT enzymes in the body which can alter the concentration of the co-administered drug to potentially harmful levels. Contraindication is also advised for Cyclosporin A Gurougn.*

FDA Label Image

5 (Image 6)

FDA Label Image

6 (Image 7)

FDA Label Image

1 (Image 8)

This is a list of acceptable birth control options. It includes various methods such as intrauterine devices, contraceptives, partner's vasectomy, diaphragm, spermicide, cervical cap, male condom, tubal sterilization, progesterone injection, vaginal ring, and progesterone implant. Each option has multiple choices to select from, and the list has been organized for easy comparison.*

FDA Label Image

1 (Image 9)

This text describes the medication Bosentan, available in tablet form with a strength of 625 mg. The medication guide should be provided with the medication, and it should be stored in a tightly closed container at a temperature between 20°C to 25°C (68°F to 77°F). The dosage must be determined in accordance with the prescription, and the directions for use must be carefully read. The manufacturing location is in Goa, India, and it is distributed in the USA by Actavis Pharma.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.